🇺🇸 FDA
Patent

US 12030958

Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides

granted A61KA61K38/57A61P

Quick answer

US patent 12030958 (Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides) held by The Regents of the University of Colorado expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K38/57, A61P, A61P13/08, A61P15/10